| 4.19 Data as of May 23 |  +0.04 / +0.96%Today’s Change | 3.21 Today|||52-Week Range 11.30 | -13.61% Year-to-Date |
| Previous close | 4.15 |
| Today’s open | 4.11 |
| Day’s range | -- - -- |
| Volume | 1,048,806 |
| Average volume (3 months) | 888,880 |
| Market cap | $555.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +52.63% |
| Earnings growth (this year) | -225.66% |
| Earnings growth (next 5 years) | -97.81% |
| Revenue growth (last year) | +902.20% |
| P/E ratio | NM |
| Price/Sales | 8.27 |
| Price/Book | 2.54 |
| Today’s change | Today’s % change | |
|---|---|---|
| KERXKeryx Biopharmaceuti... | +0.15 | +1.90% |
| SGYPSynergy Pharmaceutic... | +0.06 | +1.19% |
| SGMOSangamo BioSciences ... | +0.12 | +1.54% |
| QLTIQLT Inc | -0.05 | -0.63% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $69.7M |
| Annual profit (last year) | -$32.4M |
| Net profit margin | -46.51% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Ronald C. Renaud, Jr., MBA |
Chief Financial Officer, Treasurer & Senior VP Daniella Beckman, CPA |
Corporate headquarters Cambridge, Massachusetts |
.
